The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Time to progression and time to treatment failure in patients with triple-negative metastatic breast cancer receiving eribulin mesylate in a community oncology setting.
Claudio Faria
Employment or Leadership Position - Eisai
James Jackson
Research Funding - Eisai
Orsolya Lunacsek
Research Funding - Eisai
Kristin L. Hennenfent
Research Funding - Eisai